Jansen A Elizabeth, Rosenfeldt Anson B, Lopez-Lennon Cielita, Fernandez Hubert, Zimmerman Eric, Imrey Peter B, Dibble Leland E, Alberts Jay L
Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake, Utah, USA.
Mov Disord Clin Pract. 2025 Mar;12(3):333-339. doi: 10.1002/mdc3.14286. Epub 2024 Nov 27.
Dexterous dysfunction is a bothersome patient-reported symptom of Parkinson's disease (PD). Current clinical assessments do not directly evaluate goal-directed hand function. This project sought to determine the capability of the electronic Manual Dexterity Test (MDT) to characterize dexterity across a range of PD patients.
To objectively quantify manual dexterity in individuals with PD using a self-administered manual dexterity test.
Two hundred and forty-nine PD patients completed trials of the MDT with each upper extremity (UE) both while ON and OFF antiparkinsonian medication. Differences in MDT by medication state, more vs less affected UE, and Hoehn and Yahr (H&Y) stage were evaluated using linear mixed models. The relationships of trial duration to MDS-UPDRS II patient quality of life (QoL) questions for eating, dressing and hygiene were also evaluated.
MDT duration was significantly shorter ON medication (26.3 seconds) compared to OFF medication (27.2 seconds) (P < 0.001). Similarly, MDT duration was significantly shorter for less (25.8 seconds) compared to more (27.6 seconds) affected limb (P < 0.001). Trial durations increased with H&Y stage (P < 0.001 for trend). MDT performance was related to MDS-UPDRS II questions for eating, dressing, and hygiene performance (P < 0.001).
The MDT provides an objective and quantitative assessment of dexterity. The time to complete the MDT was sensitive to changes in medication state, more and less affected UE, disease severity, and important activities of daily living. The MDT has potential for utilization in precise tracking of manual dexterity over the course of PD.
灵巧功能障碍是帕金森病(PD)患者报告的一种令人困扰的症状。目前的临床评估并未直接评估目标导向的手部功能。本项目旨在确定电子手动灵巧性测试(MDT)对一系列PD患者的灵巧功能进行特征描述的能力。
使用自我管理的手动灵巧性测试客观量化PD患者的手动灵巧性。
249名PD患者在服用和未服用抗帕金森药物的情况下,分别用每只上肢完成MDT试验。使用线性混合模型评估MDT在药物状态、受累程度不同的上肢以及Hoehn和Yahr(H&Y)分期方面的差异。还评估了试验持续时间与MDS-UPDRS II患者在进食、穿衣和卫生方面的生活质量(QoL)问题之间的关系。
与未服药时(27.2秒)相比,服药时MDT持续时间显著缩短(26.3秒)(P<0.001)。同样,受累程度较轻的肢体(25.8秒)的MDT持续时间比受累程度较重的肢体(27.6秒)显著缩短(P<0.001)。试验持续时间随H&Y分期增加(趋势P<0.001)。MDT表现与MDS-UPDRS II中关于进食、穿衣和卫生表现的问题相关(P<0.001)。
MDT提供了一种客观且定量的灵巧性评估。完成MDT的时间对药物状态、受累程度不同的上肢、疾病严重程度以及日常生活中的重要活动的变化敏感。MDT在PD病程中精确跟踪手动灵巧性方面具有应用潜力。